Results 151 to 160 of about 6,178 (191)

Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias. [PDF]

Blood Adv
Sheth S, Lal A, Appiah-Kubi A, Peslak SA, Toiber Temin N, Chen MA, Coates T.   +6 more
europepmc   +1 more source

Iron-Responsive Deferasirox Release from Covalently Grafted Hydrogels on Microwires Extends Iron Chelation Time Scales. [PDF]

ACS Appl Mater Interfaces
Maleszka JA, Attah E, Tsironi I, Franklin M, Bernard B, Grant JL, Lee GM, Lewis M, Byrd S, Prasad A, Olivier JH.   +10 more
europepmc   +1 more source

Identification of deferasirox as a human xanthine oxidase inhibitor. [PDF]

Life Med
Qi Y, He X, Wu X, Zhou T, Liang N, Jiao J, Chen Y, Yuan Y, Zhang Y, Wang Y, Liu Y, Ding Q.   +11 more
europepmc   +1 more source

CLPX acquires an iron-sulfur cluster to sustain mitochondrial proteostasis in cancer cells. [PDF]

Nat Commun
Huang C, Zhang Y, Gao H, Song Y, Hu S, Sun C, Duan S, Ma D, Jiang X, Liu G.   +9 more
europepmc   +1 more source

Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen

Journal of Clinical Pharmacology, 2008
Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical
Maria Domenica Cappellini, Gian Luca Forni, Antonio Piga   +2 more
exaly   +3 more sources

Long-term efficacy and safety of deferasirox

Blood Reviews, 2008
Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial have established that, in transfusion-dependent patients with β ...
Maria Domenica Cappellini
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Deferasirox

American Journal of Health-System Pharmacy, 2007
The pharmacology, clinical efficacy, adverse effects and toxicities, and the economic issues that should be considered in using deferasirox are reviewed.Iron overload is a complication of the chronic blood transfusions used to treat several hematologic disorders. To date, management of transfusional iron overload has consisted of chelation therapy with
openaire   +2 more sources

Deferasirox: An Update

Hemoglobin, 2009
Cumulative data from prospective studies in over 3,000 patients with a range of transfusion dependent anemias have established key principles about the efficacy and safety of deferasirox (DFS). Pivotal preregistration studies established the relationship between dose, iron excretion, and tolerability using changes in liver iron concentration (LIC) to ...
openaire   +2 more sources

Deferasirox

Reactions Weekly, 2017
  +9 more sources

Deferasirox

Hospital Pharmacy, 2006
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Terri Levien, Danial E. Baker   +2 more
openaire   +1 more source